Toward a Definition of “No Meaningful Benefit” From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales

Carl Zhang; Sanya Virani, MD; Taryn Mayes, MS; Thomas Carmody, PhD; Paul E. Croarkin, DO; Richard Weinshilboum, MD; A. John Rush, MD; Madhukar Trivedi, MD; Arjun P. Athreya, PhD; William V. Bobo, MD

J Clin Psychiatry 2022;83(4):21m14239

ABSTRACT

Background: Many patients with major depressive disorder (MDD) who experience no meaningful benefit (NMB) from antidepressive treatment go undetected. However, there is a lack of consensus on the definition of NMB from antidepressants.

Methods: Equipercentile linking was used to identify a threshold for percent change in 17-item Hamilton Depression Rating Scale (HDRS-17) scores that equated with a Clinical Global Impressions-Improvement (CGI-I) score of 3 (minimally improved), a proxy for NMB, after 4 and 8 weeks of citalopram or escitalopram treatment, using data from the Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS). The NMB threshold for the HDRS-17 was validated by equating a CGI-I rating of 3 with percent change values from the clinician- and patient-rated versions of the Quick Inventory of Depressive Symptomatology (QIDS-C and QIDS-SR) using data from PGRN-AMPS and phase 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. This study was conducted between June 2021 and September 2021.

Results: In PGRN-AMPS, a 30% improvement in HDRS-17 score corresponded to a CGI-I rating of 3 at 4 and 8 weeks. The 30% improvement threshold was also observed for QIDS-C and QIDS-SR scores in both PGRN-AMPS and STAR*D. Similar results were observed for percent change in HDRS-17 and QIDS-based measures in lower- and higher-severity groups based on a median split of baseline total scores.

Conclusions: Improvement in depressive severity of ≤ 30%, as assessed using the HDRS-17, QIDS-C, and QIDS-SR, may validly define NMB from antidepressants during short-term treatment.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (45)

James SL, Abate D, Abate H; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. PubMed CrossRef
Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90. PubMed CrossRef
Smith K. Mental health: a world of depression. Nature. 2014;515(7526):180–181. PubMed CrossRef
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. PubMed CrossRef
Carvalho AF, Berk M, Hyphantis TN, et al. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom. 2014;83(2):70–88. PubMed CrossRef
Guo T, Xiang YT, Xiao L, et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry. 2015;172(10):1004–1013. PubMed CrossRef
Fortney JC, Unützer J, Wrenn G, et al. A tipping point for measurement-based care. Psychiatr Serv. 2017;68(2):179–188. PubMed CrossRef
Kudlow PA, McIntyre RS, Lam RW. Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs. 2014;28(7):601–609. PubMed CrossRef
Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53(9):785–792. PubMed CrossRef
Pae CU, Wang SM, Lee SY, et al. Early switch strategy in patients with major depressive disorder. Expert Rev Neurother. 2012;12(10):1185–1188. PubMed CrossRef
Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):5–9. PubMed
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179–200. PubMed CrossRef
Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service; 1976.
Busner J, Targum SD. The Clinical Global Impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37. PubMed
Spielmans GI, McFall JP. A comparative meta-analysis of Clinical Global Impressions change in antidepressant trials. J Nerv Ment Dis. 2006;194(11):845–852. PubMed CrossRef
Bobo WV, Angleró GC, Jenkins G, et al. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. Hum Psychopharmacol. 2016;31(3):185–192. PubMed CrossRef
Leucht S, Fennema H, Engel R, et al. What does the HAMD mean? J Affect Disord. 2013;148(2-3):243–248. PubMed CrossRef
Leucht S, Fennema H, Engel RR, et al. What does the MADRS mean? equipercentile linking with the CGI using a company database of mirtazapine studies. J Affect Disord. 2017;210:287–293. PubMed CrossRef
Turkoz I, Alphs L, Singh J, et al. Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. Acta Psychiatr Scand. 2021;143(3):253–263. PubMed CrossRef
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. PubMed CrossRef
Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician rating (QIDS-C), and Self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
Mrazek DA, Biernacka JM, O’Kane DJ, et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics. 2011;21(1):1–9. PubMed CrossRef
Rush AJ, South C, Jain S, et al. Clinically significant changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report. Neuropsychiatr Dis Treat. 2021;17:2333–2345. PubMed CrossRef
Dimidjian S, Hollon SD. How would we know if psychotherapy were harmful? Am Psychol. 2010;65(1):21–33. PubMed CrossRef
Greden JF. The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry. 2001;62(suppl 22):5–9. PubMed
Li J, Kuk AY, Rush AJ. A practical approach to the early identification of antidepressant medication non-responders. Psychol Med. 2012;42(2):309–316. PubMed CrossRef
Henke RM, Zaslavsky AM, McGuire TG, et al. Clinical inertia in depression treatment. Med Care. 2009;47(9):959–967. PubMed CrossRef
Gloster AT, Rinner MTB, Ioannou M, et al. Treating treatment non-responders: a meta-analysis of randomized controlled psychotherapy trials. Clin Psychol Rev. 2020;75:101810. PubMed CrossRef
Leuchter AF, Cook IA, Hunter AM, et al. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci. 2009;11(4):435–446. PubMed CrossRef
Furukawa TA, Akechi T, Azuma H, et al. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. J Clin Psychopharmacol. 2007;27(5):531–534. PubMed CrossRef
Kolen MJ, Brennan RL. Test Equating, Scaling, and Linking. Springer Link; 2004.
Kolen MJ, Brennan RL. Test Equating, Scaling, and Linking: Methods and Practices. 3rd ed. Springer Science & Business Media; 2014.
Areán PA, Alvidrez J. Treating depressive disorders: who responds, who does not respond, and who do we need to study? J Fam Pract. 2001;50(6):E2. PubMed
Corey-Lisle PK, Nash R, Stang P, et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004;164(11):1197–1204. PubMed CrossRef
Conway CR, Kumar A, Xiong W, et al. Chronic vagus nerve stimulation significantly improves quality of life in treatment-resistant major depression. J Clin Psychiatry. 2018;79(5):18m12178. PubMed CrossRef
Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care. 2007;23(1):30–35. PubMed CrossRef
Sartorius N. Patient-reported outcomes in psychiatry. Dialogues Clin Neurosci. 2014;16(2):123–124. PubMed CrossRef
Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344–353. PubMed CrossRef
Kobak KA, Brown B, Sharp I, et al. Sources of unreliability in depression ratings. J Clin Psychopharmacol. 2009;29(1):82–85. PubMed CrossRef
McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29(3):243–259. PubMed CrossRef
Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists’ selection of antidepressants? Am J Psychiatry. 2004;161(7):1285–1289. PubMed CrossRef
Husain SF, Yu R, Tang TB, et al. Validating a functional near-infrared spectroscopy diagnostic paradigm for major depressive disorder. Sci Rep. 2020;10(1):9740. PubMed CrossRef
Athreya AP, Brückl T, Binder EB, et al. Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. Neuropsychopharmacology. 2021;46(7):1272–1282. PubMed CrossRef
Athreya AP, Neavin D, Carrillo-Roa T, et al. Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication. Clin Pharmacol Ther. 2019;106(4):855–865. PubMed CrossRef